Comparative Pharmacology
Head-to-head clinical analysis: DTIC DOME versus PRALATREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DTIC DOME versus PRALATREXATE.
DTIC-DOME vs PRALATREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dacarbazine is an alkylating agent that forms methyltriazenoimidazole carboxamide, causing cross-linking of DNA and inhibition of DNA, RNA, and protein synthesis.
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
DTIC 250 mg/m2 IV daily for 5 days every 21-28 days, or 850-1000 mg/m2 IV as a single dose every 21-28 days.
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 4-7 hours) for parent drug; metabolites exhibit longer half-life (up to 8-12 hours). Clinical context: requires multiple dosing cycles due to short half-life.
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Renal (40-60% as unchanged drug and metabolites, primarily 5-aminoimidazole-4-carboxamide); biliary/fecal (minimal, <10%)
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Antineoplastic
Antineoplastic